In order to resolve these relevant questions, we are currently pursuing an experimental approach involving CRISPR/Cas9-based genetic target elimination that we have implemented successfully to explore the role of GLO1 in cancer cell lines including A375 malignancies melanoma and DU-145 PCa cells [21,44,45]. Here, GLO1 is linked to posterior cortical atrophy.